PLM 101
Alternative Names: PLD-101; PLM-101; PLM-103Latest Information Update: 01 Dec 2023
At a glance
- Originator PeLeMed
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Cancer; Liver cancer; Non-small cell lung cancer
Most Recent Events
- 01 Dec 2023 Discontinued - Preclinical for Breast cancer in South Korea (unspecified route) (PeLeMed pipeline, December 2023)
- 01 Dec 2023 Discontinued - Preclinical for Cancer in South Korea (unspecified route) (PeLeMed pipeline, December 2023)
- 01 Dec 2023 Discontinued - Preclinical for Liver cancer in South Korea (unspecified route) (PeLeMed pipeline, December 2023)